Clinical and Biological Insights into Prostate Cancer Derived from the Microfluidic Capture of Circulating Tumor Cells
About Clinical and Biological Insights into Prostate Cancer Derived from the Microfluidic Capture of Circulating Tumor Cells
The discovery of biomarkers that predict disease progression or provide a signal for effectiveness of an experimental medication for prostate cancer is a priority for PCF. These markers will increase the pace of new medication development and signal physicians earlier when prostate cancer is progressing. Dr. Haber, in collaboration with oncologists, biologists and engineers, will refine a system that measures tumor cells in patient blood. Enumeration of these cells provides an early signal of disease progression and will be clinically validated. Molecular evaluation of circulating tumor cells will be performed to better optimize prostate cancer therapy for individuals.
Massachusetts General Hospital research team members: Dr. Richard J. Lee; Dr. Shyamala S. Maheswaran; Dr. Sunitha Nagrath; Dr. Matthew R. Smith; Dr. Mehmet M. Toner.
Dr. Daniel Haber, Massachusetts General Hospital